Zions Bancorporation N.A. Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Zions Bancorporation N.A. raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2,860.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 592 shares of the biopharmaceutical company’s stock after purchasing an additional 572 shares during the period. Zions Bancorporation N.A.’s holdings in Alnylam Pharmaceuticals were worth $163,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC grew its position in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $26,000. Huntington National Bank increased its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $29,000. Finally, Altitude Crest Partners Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $30,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. This represents a 16.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. Barclays raised their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. TD Cowen boosted their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, Raymond James increased their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $294.50.

Alnylam Pharmaceuticals Stock Down 8.7 %

NASDAQ:ALNY opened at $235.56 on Friday. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The company has a market capitalization of $30.38 billion, a price-to-earnings ratio of -89.91 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The stock has a 50-day simple moving average of $274.95 and a 200 day simple moving average of $234.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The company’s quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.15 earnings per share. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.